Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 7/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14087834 | 0.94 | METAP2 (0.70) | METAP2ALDH1A1CYP1A2CYP2C9MCL1 | |
| SCHEMBL14075202 | 0.88 | METAP2 (0.62) | METAP2ALDH1A1CYP1A2CYP2C9MCL1 | |
| SCHEMBL13034755 | 0.87 | METAP2 (0.61) | METAP2ALDH1A1CYP1A2CYP2C9MCL1 | |
| SCHEMBL13034757 | 0.86 | METAP2 (0.60) | METAP2ALDH1A1CYP1A2CYP2C9MCL1 | |
| SCHEMBL3980105 | 0.85 | METAP2 (0.81) | METAP2ALDH1A1CYP1A2CYP2C9MCL1 | |
| SCHEMBL12570805 | 0.82 | METAP2 (0.86) | METAP2CYP1A2CYP2C9MCL1LMNA | |
| SCHEMBL13034754 | 0.81 | FFAR4 (0.60) | METAP2CYP1A2CYP2C9LMNAHTT | |
| SCHEMBL13034780 | 0.81 | METAP2 (0.62) | METAP2ALDH1A1CYP1A2CYP2C9MCL1 | |
| SCHEMBL13034761 | 0.81 | CYP2C9 (0.84) | METAP2ALDH1A1CYP1A2CYP2C9MCL1 | |
| SCHEMBL14397339 | 0.80 | METAP2 (0.48) | METAP2ALDH1A1CYP1A2CYP2C9MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-11-04 | — | — | US | disclosed |
| WO-2007113337-A1 | A HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280268-A1 | HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM | C1QBP, CD4, CHRM4 | METAP2 4039/4885ALDH1A1 4806/4885CYP1A2 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.